Finerenone, Eplerenone, and Spironolactone in HFpEF: A Bayesian Network Meta-Analysis of Efficacy and Safety - PubMed
3 hours ago
- #mineralocorticoid receptor antagonists
- #HFpEF
- #meta-analysis
- Comparative effects of mineralocorticoid receptor antagonists (MRAs) in HFpEF/HFmrEF were analyzed.
- Finerenone significantly reduced hospitalization for HF versus placebo (RR 0.84; 95% CrI 0.75-0.93).
- Spironolactone and eplerenone showed nonsignificant effects on hospitalization for HF.
- None of the MRAs significantly reduced cardiovascular mortality compared to placebo.
- All MRAs increased hyperkalemia risk versus placebo.
- Finerenone may offer the most favorable efficacy-safety balance among MRAs.